Free Trial

Telix Pharmaceuticals (TLX) Earnings Date, Estimates & Call Transcripts

Telix Pharmaceuticals logo
$10.52 +0.13 (+1.25%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$10.53 +0.01 (+0.10%)
As of 05/13/2026 05:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Telix Pharmaceuticals Earnings Summary

Telix Pharmaceuticals issued H2 2025 earnings on February 20, 2026, reporting an EPS of -$0.01, which missed the consensus estimate of $0.05 by $0.06. Quarterly revenue was reported to be $206.72 million, below analyst estimates of $421.50 million. With a trailing EPS of $0.00, Telix Pharmaceuticals' earnings are expected to grow 88.89% next year, from $0.09 to $0.17 per share.

Latest H2
Earnings Date
Feb. 20Estimated
Consensus EPS
(Feb. 20)
$0.05
Actual EPS
(Feb. 20)
-$0.01 Missed By -$0.06
Actual Revenue
(Feb. 20)
$206.72M

H2 2025 Earnings Resources

Get Telix Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Telix Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Telix Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Revenue Guidance
Q1 20261$0.04$0.04$0.04$230.0 M - $230.0 M
Q2 20261$0.05$0.05$0.05
Q3 20261$0.06$0.06$0.06
Q4 20261$0.07$0.07$0.07
FY 2026 4 $0.22 $0.22 $0.22
Q1 20271$0.09$0.09$0.09
Q2 20271$0.09$0.09$0.09
Q3 20271$0.10$0.10$0.10

Telix Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
2/20/2026H2 2025$0.0493-$0.01 -$0.0593-$0.0070$421.50M$206.72M

Data powered by Fiscal.ai.

Telix Pharmaceuticals Earnings - Frequently Asked Questions

Telix Pharmaceuticals (NASDAQ:TLX) last announced its quarterly earning data on Friday, February 20, 2026. Learn more on TLX's earnings history.

Telix Pharmaceuticals updated its FY 2026 earnings guidance on Thursday, April, 9th. The company issued revenue guidance of $950.0 million-$970.0 million.

In the previous quarter, Telix Pharmaceuticals (NASDAQ:TLX) missed the analysts' consensus estimate of $0.05 by $0.06 with a reported earnings per share (EPS) of ($0.01). Learn more on analysts' earnings estimate vs. TLX's actual earnings.

The conference call for Telix Pharmaceuticals' latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Telix Pharmaceuticals' latest earnings report can be read online.
Read Transcript

Telix Pharmaceuticals (NASDAQ:TLX) has a recorded annual revenue of $803.79 million.

Telix Pharmaceuticals (NASDAQ:TLX) has a recorded net income of -$7.12 million. TLX has generated $0.00 earnings per share over the last four quarters.

Telix Pharmaceuticals' earnings are expected to grow from $0.09 per share to $0.17 per share in the next year, which is a 88.89% increase.


This page (NASDAQ:TLX) was last updated on 5/14/2026 by MarketBeat.com Staff.
From Our Partners